KymaThera Builds Precision Medicines Around Selectivity

KymaThera is a San Diego biotechnology company building small-molecule precision medicines around a specific idea: validated biology can still produce disappointing drugs when selectivity, mutation coverage or exposure are wrong. The company applies structure-based drug design to targets in cancer, vascular malformations and fibrotic disease.

Founder and CEO Rob Kania leads KymaThera alongside co-founders Jason Cox, Brooke Grandinetti and Shawn Ouyang. Their backgrounds span Pfizer, Merck, Kinnate Biopharma, Vertex, Novartis, Amgen and ImClone. The team is small, but its collective résumé includes approved medicines, development candidates and decades spent learning where otherwise credible drug programs break.

KymaThera matters now because its lead candidate, K-1728, is approaching the point where design claims become clinical questions. An $80M Series B gives the company capital to begin Phase 1 dosing in Q4 2026 and seek initial proof-of-concept. For the broader biotechnology market, the wager is familiar and difficult: better chemistry can reopen targets the industry already knows, but only patients can validate the promised improvement.

About KymaThera

KymaThera was founded in 2024 as a privately held biotechnology company focused on precision therapeutics. Its stated discovery framework combines molecular insight with strategic structure-based design to optimize small-molecule properties rather than treating target selection as the whole invention.

That distinction shapes the pipeline. KymaThera is working on PI3Kα, ALK5 and JAK2, pathways with substantial biological evidence and previous drug-development activity. The company is not claiming to have found 3 untouched targets hiding under a lab bench. It is arguing that the remaining opportunity sits in the profile of the molecule: what it hits, what it spares, where it goes and how long useful exposure can be maintained.

The company has disclosed more than $100M in total capital. Alta Partners led its October 2026 Series B, with Venrock, Foresite Capital, J. Wood Capital and others participating. Venrock's company profile records its first KymaThera investment as a 2024 seed round.

K-1728 Puts Selectivity at the Center

KymaThera's lead candidate, K-1728, is an investigational oral pan-mutant selective PI3Kα inhibitor. The company pipeline says the molecule is designed to cover disease-driving mutations in both the kinase and helical domains while sparing wild-type PI3Kα.

That is a product-design response to a known therapeutic problem. PI3Kα is clinically validated in PIK3CA-mutated breast cancer and PIK3CA-related overgrowth spectrum. FDA records document alpelisib's approval in severe PIK3CA-related overgrowth spectrum, while the target also has approved use in HR-positive/HER2-negative breast cancer.

Validation does not remove the tradeoffs. PI3Kα supports normal metabolic biology, and clinical guidance identifies hyperglycemia as an important treatment-associated effect. KymaThera's thesis is that broader mutant coverage and less wild-type inhibition could support a more useful dosing window.

The company reports tumor regressions at low once-daily doses in preclinical models and an exposure window before hyperglycemia-associated levels. Those are company-reported preclinical findings, not evidence of safety or efficacy in people. K-1728's planned Phase 1 study must establish how the molecule behaves in human patients.

One Design Logic Across 3 Programs

K-1728 is planned for 2 initial disease settings. KymaThera intends to study it in HR-positive/HER2-negative breast cancer as a monotherapy and in combinations, and in PI3Kα-driven vascular malformations as a monotherapy. The diseases have different treatment goals, but both programs depend on the same proposed separation between mutant and wild-type biology.

The rest of KymaThera's disclosed pipeline extends that design logic. An inhaled ALK5 inhibitor is being developed for pulmonary fibrosis with the aim of producing restricted, durable lung exposure and limited systemic distribution. A mutant-selective JAK2 program for myeloproliferative neoplasms is intended to improve ligand efficiency, drug-like properties and tolerability relative to less selective approaches.

Both programs remain preclinical, and their claimed advantages have not been established in patients. Together, however, they make KymaThera's operating thesis legible. The company is looking for cases where localization or selectivity may be as important as target choice.

A Team Built Around Drug-Discovery Scar Tissue

KymaThera's leadership is unusually concentrated in discovery chemistry and translational biology. Rob Kania spent more than 20 years at Pfizer, where he led research programs and oncology medicinal chemistry and design groups. The company credits him with contributing to more than 20 development candidates, including work connected to approved medicines such as Inlyta, Xalkori, Lorbrena and Paxlovid. Before KymaThera, he was Senior Vice President of Research at Kinnate Biopharma.

Jason Cox, KymaThera's CSO, spent 16 years at Merck and later led discovery chemistry at Kinnate. Brooke Grandinetti, Vice President of Biology, previously guided discovery biology at Kinnate and worked at Vertex, Novartis and Shire. Shawn Ouyang, Senior Director of Discovery Chemistry, came through Kinnate, Sumo Biosciences, Amgen and ImClone.

Chief Medical Officer Cassandra Choe-Juliak brings oncology-development experience, while Chief Financial Officer Michael Geremia adds financing, planning and operations experience across venture-backed biotechnology companies. That mix matters because KymaThera is crossing from a discovery-led company into a clinical organization. Chemistry may shape the asset, but trial design, operations and capital discipline will decide how quickly the hypothesis can be tested.

Why KymaThera Matters Right Now

The biotech industry often celebrates target novelty because it is easy to package as a clean origin story. KymaThera is built around a messier truth. Some of the biggest opportunities sit inside targets everyone already knows, where previous generations of molecules exposed both the value of the biology and the cost of an imperfect profile.

That strategy reduces one kind of uncertainty and concentrates another. The company can point to target validation, known disease relevance and a defined competitive landscape. It still has to prove that its molecules create enough differentiation to matter clinically, not merely enough to look elegant in a preclinical chart.

KymaThera does not currently publish a dedicated careers page or a stable list of open roles. Its official site does invite scientists, operators and potential partners to contact the team around its mission and programs. The more meaningful growth signal is the build from discovery into clinical execution as K-1728 approaches first-in-human testing.

The next chapter will not be written by the amount raised or the number of experienced names on the team. It will be written by dose, exposure, tolerability and biological activity in patients. If K-1728 translates, KymaThera will have more than a lead asset. It will have early evidence that its design framework can turn hard-earned lessons from established targets into a repeatable company.